NCT05813665View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

September 30, 2028

Conditions
Giant Cell Tumor of Bone
Interventions
DRUG

Narlumosbart

Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.

DRUG

Denosumab

Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.

Trial Locations (1)

100035

Beijing Ji Shui Tan Hospital, Beijing

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT05813665 - A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | Biotech Hunter | Biotech Hunter